Critical Review: Whitehawk Therapeutics (WHWK) versus Its Competitors

Whitehawk Therapeutics (NASDAQ:WHWK) is one of 451 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its rivals? We will compare Whitehawk Therapeutics to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, dividends, profitability and risk.

Profitability

This table compares Whitehawk Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	99.42%	-75.99%	-68.57%
Whitehawk Therapeutics Competitors	-2,625.49%	-359.63%	-43.39%

Volatility and Risk

Whitehawk Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics’ rivals have a beta of 10.31, suggesting that their average stock price is 931% more volatile than the S&P 500.

Valuation and Earnings

This table compares Whitehawk Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Whitehawk Therapeutics	$25.98 million	-$63.69 million	-44.33
Whitehawk Therapeutics Competitors	$439.20 million	-$68.89 million	-9.21

Whitehawk Therapeutics’ rivals have higher revenue, but lower earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Whitehawk Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	0	0	1.50
Whitehawk Therapeutics Competitors	4783	9955	15978	370	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 92.06%. Given Whitehawk Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Whitehawk Therapeutics rivals beat Whitehawk Therapeutics on 8 of the 13 factors compared.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.